ロルカセリン
参考資料

↑  “Lorcaserin Use During Pregnancy”. Drugs.com (4 November 2019). 14 January 2020閲覧。
1 2  “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”. U.S. Food and Drug Administration (FDA) (14 January 2020). 1 April 2020閲覧。
1 2 3 4 5  “Belviq (lorcaserin hydrochloride) tablet [Eisai, Inc]”. DailyMed.   Eisai, Inc (August 2012). 21 October 2013時点のオリジナルよりアーカイブ。21 October 2013閲覧。
1 2 3 4 5  "FDA approves Belviq to treat some overweight or obese adults". U.S. Food and Drug Administration (FDA) (Press release). 27 June 2012. 2012年9月1日時点のオリジナルよりアーカイブ。2020年1月14日閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
↑  “Belviq”.   Trademarkia (23 Jun 2011). 30 June 2012時点のオリジナルよりアーカイブ。27 June 2012閲覧。
↑  “Lorcaserin Hcl for the treatment of obesity”. Expert Opinion on Pharmacotherapy 16 (16):  2531–8. (2015). doi:10.1517/14656566.2015.1096345. PMID 26472579.
↑  “Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug”. U.S. Food and Drug Administration (FDA) (13 February 2020). 18 February 2020閲覧。
↑  “Management of obesity”. Lancet 387 (10031):  1947–56. (May 2016). doi:10.1016/S0140-6736(16)00271-3. PMID 26868660.
1 2  Wilson, Megan R. (December 19, 2012). “Reg Watch”. The Hill.  オリジナルのMarch 20, 2013時点におけるアーカイブ。. https://web.archive.org/web/20130320092432/https://thehill.com/business-a-lobbying/273901-reg-watch
↑  “Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV” (2012年12月19日). 2021年6月14日閲覧。
↑  “Department Of Justice Drug Enforcement Administration 21 CFR Part 1308, Placement of Lorcaserin into Schedule IV” (2013年5月8日). 2021年6月14日閲覧。
↑  “Safety and tolerability of new-generation anti-obesity medications: a narrative review”. Postgraduate Medicine 130 (2):  173–182. (March 2018). doi:10.1080/00325481.2018.1435129. PMC 6261426. PMID 29388462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261426/.
↑  “Safety and tolerability review of lorcaserin in clinical trials”. Clinical Obesity 6 (5):  285–95. (October 2016). doi:10.1111/cob.12159. PMID 27627785.
↑  “Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)”. U.S. Food and Drug Administration (FDA) (14 January 2020). 14 January 2020閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
↑  “Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization”. The Journal of Pharmacology and Experimental Therapeutics 325 (2):  577–87. (May 2008). doi:10.1124/jpet.107.133348. PMID 18252809. https://semanticscholar.org/paper/e7229f55f3a5d33c42f2706b2ab787acb81773c1.
↑  Zhu Q, et al. Novel Synthesis of Antiobesity Drug Lorcaserin Hydrochloride. Org. Process Res. Dev. 2015, 19(9): 1263–1267. doi:10.1021/acs.oprd.5b00144
↑  US patent 6953787, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2003-10-04, issued 2005-11-10
↑  US patent 7704993, Brian Smith, Charles A. Gilson, III, Jeffrey Schultz, Jeffrey Smith, "Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases", published 2004-16-06, issued 2010-27-04
↑  US patent 8207158, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2011-27-05, issued 2012-26-06
↑  “Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity”. Journal of Medicinal Chemistry 51 (2):  305–13. (January 2008). doi:10.1021/jm0709034. PMID 18095642.
↑  “Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity”. Bioorganic & Medicinal Chemistry Letters 15 (5):  1467–70. (March 2005). doi:10.1016/j.bmcl.2004.12.080. PMID 15713408.
↑  Spreitzer, Helmut (13 September 2010). “Lorcaserin” (ドイツ語). Österreichische Apothekerzeitung 64 (19):  1083.
↑  “Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies”. Therapie 60 (5):  441–60. (2005). doi:10.2515/therapie:2005065. PMID 16433010.
↑  “Lorcaserin New Drug Application”.   Drugs.com (22 December 2009). 3 March 2016時点のオリジナルよりアーカイブ。2021年6月14日閲覧。
↑  Pollack, Andrew (16 September 2010). “F.D.A. Panel Rejects Diet Pill”. The New York Times.  オリジナルの17 July 2011時点におけるアーカイブ。. https://web.archive.org/web/20110717034008/http://prescriptions.blogs.nytimes.com/2010/09/16/f-d-a-panel-rejects-diet-pill-2/?pagemode=print
↑  Pollack, Andrew (16 September 2010). “F.D.A. Panel Urges Denial of Diet Drug”. The New York Times.  オリジナルの22 August 2017時点におけるアーカイブ。. https://web.archive.org/web/20170822060100/http://www.nytimes.com/2010/09/17/health/17drug.html?hpw
↑  “FDA Issues Complete Response Letter for Lorcaserin New Drug Application”. (23 October 2010).  オリジナルの24 October 2010時点におけるアーカイブ。. https://web.archive.org/web/20101024221021/http://www.prnewswire.com/news-releases/fda-issues-complete-response-letter-for-lorcaserin-new-drug-application-105586113.html
↑  “New Diet Drug Lorcaserin Wins Vote From FDA Panel”.   webmd (10 May 2012). 12 May 2012時点のオリジナルよりアーカイブ。2021年6月14日閲覧。
↑  “Drug Approval Package: Belviq (lorcaserin hydrochloride) Tablets NDA #022529”. U.S. Food and Drug Administration (FDA) (August 7, 2012). 14 January 2020閲覧。
↑  “Belviq XR (lorcaserin hydrochloride) extended-release tablets”. U.S. Food and Drug Administration (FDA) (26 October 2016). 14 January 2020閲覧。
↑  “FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer”. FDA. (2020年2月13日). https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requests-voluntary-withdrawal-weight-loss-medication-after-clinical-trial-shows